Unified Program for Therapeutics in Children (UPTiC)

儿童治疗统一计划 (UPTiC)

基本信息

  • 批准号:
    10159122
  • 负责人:
  • 金额:
    $ 50.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

The development pipeline for prophylactics and therapeutics that target pediatric diseases is sparse compared to that of adults. A gap in the understanding of pediatric physician-scientists regarding how to span this translational divide compromises the development of promising therapies. The primary goal of this Unified Program for Therapeutics in Children (UPTiC) is to train young pediatric physician-scientists with strong academic potential to lead the development of novel therapeutics and prophylactics for children and be thought- leaders in the field of pediatric drug development. The program will train subspecialty pediatric fellows in 3 tracks that span the full pipeline of clinical development: 1) discovery-based research (preclinical/translational pediatric drug development), 2) clinical pediatric trials, and 3) outcomes/real world evidence. The program will cover three major training aims, including: 1) individualized didactic and degree-oriented course work in pediatric drug development, 2) mentored training in preclinical, clinical trials, and outcomes research, and 3) grant-writing training and mock review. The training of these pediatric research fellows will be through a combined effort bringing together the Duke University School of Medicine, including the Department of Pediatrics and the Duke Clinical Research Institute, and the University of North Carolina at Chapel Hill, including the Department of Pediatrics, School of Pharmacy, and School of Public Health. UPTiC will be led by a team of multi- university, multi-disciplinary, well-funded, and experienced faculty members, including 39 full-time Duke and UNC faculty members in Pediatrics and other basic, translational, and clinical science departments. This application requests support for six postdoctoral pediatric trainees (three new fellows per year, 2 years of support each). Trainees will be nationally recruited through established pediatric clinical trials networks led by the Duke Clinical Research Institute and Duke/UNC pediatric fellowship program directors and subsequently drawn from the pool of pediatric fellows at Duke and UNC. Individuals appointed to the training program will be named Katz- Denny Fellows. The training will center on research ongoing in the various faculty members' research groups across the Duke Medical Center and the University of North Carolina and a joint didactic program focusing on the therapeutic development pipeline for children. Upon completion of this training program, these pediatrician- scientists will be capable of not only leading translational and clinical pediatric-focused therapeutic development research, but also mentoring the next generation of pediatricians in the fundamentals of pediatric clinically- oriented research. Fulfillment of the program's objective would directly or indirectly address two imperatives: 1) the need for more full-time academic pediatric physician-researchers and mentors in medical schools throughout the country and 2) the unmet need for innovations and clinical translation of novel pediatric prevention and treatment strategies to improve the health of the youngest and most vulnerable members of our society.
相比之下 对成年人的。在理解小儿医师科学家如何跨越此事的差距 翻译划分损害了有前途的疗法的发展。这个统一的主要目标 儿童治疗计划(UPTIT)是培训年轻的儿科医师科学家 领导新的治疗学和预防药物的学术潜力,并被思考 - 小儿药物开发领域的领导者。该计划将在三首曲目中训练亚专科小儿研究员 跨越临床发展的完整管道:1)基于发现的研究(临床前/翻译 小儿药物开发),2)临床小儿试验和3)结果/现实世界证据。这 计划将涵盖三个主要的培训目标,包括:1)个性化的教学课程和以学位为导向的课程 小儿药物开发的工作,2)临床前,临床试验和结果研究的指导培训, 3)授予写作培训和模拟审查。这些小儿研究研究员的培训将是通过 将杜克大学医学院(包括儿科系)汇集在一起​​的共同努力 以及杜克临床研究所以及北卡罗来纳大学教堂山的大学,包括 儿科,药学院和公共卫生学院。 UPTIC将由一个多人团队领导 大学,多学科,资金丰富且经验丰富的教职员工,包括39名专职公爵和 UNC的儿科以及其他基本,转化和临床科学部门的教师。这 申请请求支持六名博士后小儿学员(每年三名新研究员,2年的支持 每个)。学员将通过由公爵领导的既定儿科临床试验网络招募全国招募 临床研究所和杜克/UNC儿科奖学金计划主管,随后从 杜克和UNC的小儿研究员池。任命为培训计划的个人将被任命为Katz- 丹尼家伙。该培训将在各个教师研究小组中正在进行的研究中心 在杜克大学医学中心和北卡罗来纳大学以及一个关注的联合教学计划 儿童的治疗发展管道。完成该培训计划后,这些儿科医生 - 科学家将不仅能够领导转化和临床儿科的治疗发展 研究,但也指导下一代儿科医生在儿科临床的基本面 定向研究。实现该计划的目标将直接或间接解决两个要塞:1) 需要更多的全职学术儿科医师研究者和医学院的导师 国家和2)未满足的创新需求和新型儿科预防和临床翻译 改善我们社会中最年轻,最脆弱的成员的健康的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian J Davis其他文献

Ian J Davis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian J Davis', 18)}}的其他基金

Developmental control of chromatin states in cancer
癌症中染色质状态的发育控制
  • 批准号:
    10567242
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10211263
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10580496
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10381604
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10576937
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Unified Program for Therapeutics in Children (UPTiC)
儿童治疗统一计划 (UPTiC)
  • 批准号:
    10400848
  • 财政年份:
    2019
  • 资助金额:
    $ 50.71万
  • 项目类别:
Unified Program for Therapeutics in Children (UPTiC)
儿童治疗统一计划 (UPTiC)
  • 批准号:
    10676078
  • 财政年份:
    2019
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9248144
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9150499
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9751217
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:

相似国自然基金

新型RIPK1抑制剂调控程序性坏死治疗噬血细胞综合征的作用及机制研究
  • 批准号:
    82370192
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
智能响应微针的构建及其时空控制程序性免疫治疗黑色素瘤机制研究
  • 批准号:
    22308278
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于程序性靶向纳米ROS双向调节器的胃癌联合免疫治疗新策略
  • 批准号:
    82272690
  • 批准年份:
    2022
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目
设计、构建X-射线辐射闪烁体发光系统诱导“炎性-程序性细胞死亡”及其在抗肿瘤治疗中的应用研究
  • 批准号:
    32271485
  • 批准年份:
    2022
  • 资助金额:
    54.00 万元
  • 项目类别:
    面上项目

相似海外基金

Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
  • 批准号:
    10551184
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Quorum Sensing Regulation of EHEC Virulence Genes
肠出血性大肠杆菌毒力基因的群体感应调控
  • 批准号:
    10384063
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Discovery of neoepitope immunotherapeutic targets in diffuse pediatric high-grade gliomas
弥漫性儿童高级别胶质瘤中新表位免疫治疗靶点的发现
  • 批准号:
    10774404
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
ETS1-dependent combinatorial control of oncogenic transcription in Notch-activated T-ALL
Notch激活的T-ALL中致癌转录的ETS1依赖性组合控制
  • 批准号:
    10733945
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Characterization of the Regulation and Gene Targets of TBX2 in Rhabdomyosarcoma
横纹肌肉瘤中 TBX2 的调控和基因靶点的表征
  • 批准号:
    10731025
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了